NRIX
Nurix TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
NRIX Profile
Nurix Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops targeted protein modulation drugs
1600 Sierra Point Parkway, Brisbane, CA 94005
--
Nurix Therapeutics, Inc., was incorporated in Delaware on August 27, 2009 and is headquartered in Brisbane, California. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein-degrading drugs designed to improve treatment options for patients with cancer and inflammatory diseases. Backed by an artificial intelligence (AI) integrated discovery engine and deep expertise in E3 ligase biology, the company advances a differentiated approach to translate protein degradation science into clinical therapies. Nurix's wholly-owned pipeline includes research candidates for Bruton's tyrosine kinase (BTK) and Casitas B-line lymphoma proto-oncogene B (CBL-B), as well as additional degrading agents and degrading agent antibody conjugates in preclinical development. Working with global pharmaceutical partners including Gilead Sciences, Sanofi and Pfizer, Nurix also conducts discovery programs for multiple drug candidates under co-development and co-commercialization arrangements.
